ProQR Therapeutics Creating RNA therapies for patients in need
On a mission
At ProQR, we are passionate about pushing the boundaries of science and technology to create innovative solutions for unmet medical needs. Our team is dedicated to conducting cutting-edge research and development in the RNA editing field to improve the lives of patients and families affected by genetic disorders.
We believe that every person deserves access to the best possible care, and we are committed to working together as a community to make that happen. Join us on our mission to make a real difference in the lives of those we serve.
Our science
Interne link Working at ProQRLatest press releases
-
Interne link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
-
Interne link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
-
Interne link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
ProQR Community News
-
Embracing Diversity: Why it Matters
Community news -
Catching up with returning ProQRian René Beukema
Community news -
Exploring why companies partner their technology
Community news
ProQR & Eli Lilly and Company partnership
Since 2021 ProQR has partnered with Eli Lilly and Company focusing on the discovery, development, and commercialization of potential new using ProQR’s proprietary Axiomer® RNA editing platform.
Interne link Read about our partnership